EVU guidelines recommend that PSA levels greater than 0.2 ng/mL and results influence subsequent treatment decisions, imaging of biochemically recurrent PCa with PSMA-labeled PET/CT (74). The gene discussed is KLK3; the disease is posterior cortical atrophy.